HealthPoint Plus, Inc. Announces Plan to File S-1 Registration Statement with the SEC to Register its Securities for Public Trading

NASDAQ Market News

NEXT STORY
Immunomedics Reports Results For Period Ended December 31, 2018, Strengthens Board And Announces Senior Leadership Changes
PREV STORY
Sanofi: Positive results presented from two Phase 3 trials of Dupixent® (dupilumab) in severe chronic rhinosinusitis with nasal polyps
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Cidara Therapeutics and Mundipharma Announce Positive Topline Results from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

author_avatar
NASDAQ Market News

Black Diamond Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference

author_avatar
NASDAQ Market News

Clene Reports Second Quarter 2021 Operating and Financial Highlights

author_avatar
NASDAQ Market News